Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTNM Contineum Therapeutics	$7.38 +1.7%	$4.92	$3.35 ▼ $20.55	$206.95M	1.04	316,436 shs	70,099 shs
GYRE Gyre Therapeutics	$8.14 -1.0%	$7.65	$6.11 ▼ $19.00	$783.99M	1.8	79,304 shs	61,069 shs
MRVI Maravai LifeSciences	$2.61 +0.4%	$2.42	$1.66 ▼ $9.95	$664.66M	0.28	1.73 million shs	837,445 shs
SIGA Siga Technologies	$8.50 -0.9%	$6.96	$4.95 ▼ $11.91	$608.65M	0.94	591,319 shs	466,389 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTNM Contineum Therapeutics	0.00%	+14.06%	+92.19%	+110.26%	-57.29%
GYRE Gyre Therapeutics	0.00%	+13.21%	+10.15%	-28.28%	-18.44%
MRVI Maravai LifeSciences	0.00%	+18.64%	+3.98%	+24.29%	-68.25%
SIGA Siga Technologies	0.00%	-5.13%	+26.87%	+41.90%	-28.99%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTNM Contineum Therapeutics	3.4864 of 5 stars	3.6	5.0	0.0	3.9	0.8	0.6
GYRE Gyre Therapeutics	0.0775 of 5 stars	0.0	1.0	0.0	1.7	0.8	0.0
MRVI Maravai LifeSciences	3.7049 of 5 stars	3.1	3.0	4.4	1.1	0.8	0.6
SIGA Siga Technologies	2.1585 of 5 stars	0.0	2.0	0.0	2.7	0.8	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTNM Contineum Therapeutics	3.17	Buy	$22.50	204.88% Upside
GYRE Gyre Therapeutics	3.00	Buy	N/A	N/A
MRVI Maravai LifeSciences	2.25	Hold	$5.75	120.31% Upside
SIGA Siga Technologies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CTNM, SIGA, GYRE, and MRVI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	MRVI Maravai LifeSciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$7.00 ➝ $5.00
6/20/2025	CTNM Contineum Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
5/19/2025	CTNM Contineum Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$25.00 ➝ $20.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTNM Contineum Therapeutics	$50M	4.14	N/A	N/A	$6.11 per share	1.21
GYRE Gyre Therapeutics	$105.76M	7.41	$0.20 per share	41.22	$1.34 per share	6.07
MRVI Maravai LifeSciences	$219.83M	3.02	$0.62 per share	4.22	$1.84 per share	1.42
SIGA Siga Technologies	$179.64M	3.39	$0.84 per share	10.16	$2.92 per share	2.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTNM Contineum Therapeutics	-$42.26M	-$2.20	N/A	N/A	N/A	N/A	-29.75%	-28.08%	11/5/2025 (Estimated)
GYRE Gyre Therapeutics	$12.09M	$0.01	814.81	∞	N/A	4.08%	7.67%	6.19%	N/A
MRVI Maravai LifeSciences	-$144.85M	-$1.36	N/A	N/A	N/A	-90.03%	-17.60%	-9.30%	N/A
SIGA Siga Technologies	$59.21M	$1.13	7.52	6.80	N/A	45.73%	40.52%	35.62%	N/A

Latest CTNM, SIGA, GYRE, and MRVI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	GYRE Gyre Therapeutics	$0.03	$0.02	-$0.01	$0.04	$30.80 million	$26.77 million
8/5/2025	Q2 2025	CTNM Contineum Therapeutics	-$0.56	-$0.62	-$0.06	-$0.62	$7.50 million	N/A
8/5/2025	Q2 2025	SIGA Siga Technologies	N/A	$0.49	N/A	$0.49	N/A	$81.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
GYRE Gyre Therapeutics	N/A	N/A	N/A	N/A	N/A
MRVI Maravai LifeSciences	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTNM Contineum Therapeutics	N/A	24.51	24.51
GYRE Gyre Therapeutics	N/A	5.40	3.19
MRVI Maravai LifeSciences	0.68	5.16	5.17
SIGA Siga Technologies	N/A	10.09	8.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTNM Contineum Therapeutics	N/A
GYRE Gyre Therapeutics	23.99%
MRVI Maravai LifeSciences	50.25%
SIGA Siga Technologies	55.40%

Insider Ownership

Company	Insider Ownership
CTNM Contineum Therapeutics	11.30%
GYRE Gyre Therapeutics	10.00%
MRVI Maravai LifeSciences	2.11%
SIGA Siga Technologies	1.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTNM Contineum Therapeutics	31	28.04 million	24.87 million	N/A
GYRE Gyre Therapeutics	40	96.31 million	86.68 million	No Data
MRVI Maravai LifeSciences	610	254.66 million	249.29 million	Optionable
SIGA Siga Technologies	40	71.61 million	70.21 million	Optionable

CTNM, SIGA, GYRE, and MRVI Headlines

Recent News About These Companies

Siga Technologies (NASDAQ:SIGA) Trading Down 4.9% - Should You Sell?

August 15 at 6:20 PM | marketbeat.com

Siga Technologies (NASDAQ:SIGA) Rating Increased to Strong-Buy at Wall Street Zen

August 11, 2025 | americanbankingnews.com

Wall Street Zen Upgrades Siga Technologies (NASDAQ:SIGA) to Strong-Buy

August 10, 2025 | marketbeat.com

SIGA Technologies Second Quarter 2025 Earnings: EPS: US$0.50 (vs US$0.026 in 2Q 2024)

August 8, 2025 | finance.yahoo.com

Siga Technologies (NASDAQ:SIGA) Trading 13.9% Higher - Here's Why

August 7, 2025 | marketbeat.com

SIGA (SIGA) Q2 Revenue Soars 272%

August 7, 2025 | theglobeandmail.com

Siga Technologies Sees Unusually Large Options Volume (NASDAQ:SIGA)

August 7, 2025 | marketbeat.com

Siga Technologies (NASDAQ:SIGA) Issues Earnings Results

August 6, 2025 | marketbeat.com

SIGA Technologies (SIGA) Reports Significant Earnings Decline

August 6, 2025 | finance.yahoo.com

SIGA advances pediatric and PEP programs as product revenues reach $79M, supported by new BARDA funding

August 6, 2025 | msn.com

SIGA Technologies, Inc. (SIGA) Q2 2025 Earnings Call Transcript

August 6, 2025 | seekingalpha.com

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025

August 5, 2025 | globenewswire.com

SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results

July 29, 2025 | globenewswire.com

Royce & Associates LP Has $4.16 Million Holdings in Siga Technologies Inc. (NASDAQ:SIGA)

July 28, 2025 | marketbeat.com

Siga Technologies Inc. (SIGA) Stock Falls Amid Market Uptick: What Investors Need to Know

July 24, 2025 | zacks.com

Traders Buy Large Volume of Call Options on Siga Technologies (NASDAQ:SIGA)

July 24, 2025 | marketbeat.com

Siga Technologies Inc. (SIGA) Dips More Than Broader Market: What You Should Know

July 15, 2025 | msn.com

US Market's Undiscovered Gems Featuring Three Promising Small Caps

July 15, 2025 | finance.yahoo.com

Siga Technologies Inc. (SIGA) Laps the Stock Market: Here's Why

July 9, 2025 | zacks.com

SIGA Technologies Inc Dividends - Morningstar

July 8, 2025 | morningstar.comM

Why Siga Technologies Inc. (SIGA) Outpaced the Stock Market Today

June 26, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM, SIGA, GYRE, and MRVI Company Descriptions

Contineum Therapeutics NASDAQ:CTNM

$7.38 +0.12 (+1.65%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$7.36 -0.01 (-0.20%)

As of 08/15/2025 04:14 PM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Gyre Therapeutics NASDAQ:GYRE

$8.14 -0.08 (-0.97%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$8.11 -0.03 (-0.37%)

As of 08/15/2025 06:45 PM Eastern

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Maravai LifeSciences NASDAQ:MRVI

$2.61 +0.01 (+0.38%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.58 -0.03 (-1.34%)

As of 08/15/2025 06:49 PM Eastern

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Siga Technologies NASDAQ:SIGA

$8.50 -0.08 (-0.93%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$8.50 0.00 (0.00%)

As of 08/15/2025 07:54 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time